2023
674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients
Chung C, Adkins D, Dimitrios Colevas A, Rodriguez C, Park J, Gibson M, Sukari A, Burtness B, Johnson F, Julian R, Saba N, Worden F, Dunn L, Seiwert T, Jotte R, Haddad R, Gabrail N, Bauman J, Chaney M, Agensky L, Goel A, Quayle S, Margossian S, Levisetti M, Pai S. 674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients. 2023, a764-a764. DOI: 10.1136/jitc-2023-sitc2023.0674.Peer-Reviewed Original Research
2019
Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy
LOGANADANE G, KANN BH, PARK HS, JOHNSON SB, MEHRA S, JUDSON BL, BHATIA A, BELKACEMI Y, YARBROUGH WG, BURTNESS B, HUSAIN ZA. Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Research 2019, 39: 4885-4890. PMID: 31519591, DOI: 10.21873/anticanres.13674.Peer-Reviewed Original ResearchConceptsLocoregional recurrence-free survivalAdjuvant therapyNeck squamous cell carcinomaOutcomes of patientsRecurrence-free survivalSquamous cell carcinomaNeck cancer patientsHNSCC patientsClinical outcomesRecurrence rateCell carcinomaMean TTPCancer patientsPatientsTherapyResectionMonthsOutcomesHNSCCSurgeryCarcinomaHeadIncidenceProgression
2017
NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis
Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA. NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nature Communications 2017, 8: 1772. PMID: 29176703, PMCID: PMC5701248, DOI: 10.1038/s41467-017-01877-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesFemaleGene Expression Regulation, NeoplasticHistone MethyltransferasesHistone-Lysine N-MethyltransferaseHumansIntracellular Signaling Peptides and ProteinsLaryngeal NeoplasmsMaleMiddle AgedMutationNuclear ProteinsPrognosisRepressor ProteinsSquamous Cell Carcinoma of Head and NeckConceptsUseful clinical metricSquamous cell carcinomaLaryngeal cancer patientsPoor overall survivalIndependent validation cohortDistinct prognostic outcomesMolecular prognostic biomarkersOverall survivalCancer Genome AtlasFavorable prognosisBetter prognosisValidation cohortCell carcinomaCancer patientsLaryngeal tumorsLaryngeal cancerPrognostic outcomesTreatment stratificationPrognostic biomarkerNasal cavityOral cavityHigh recurrenceAnatomical sitesPatient stratificationCancer subtypesSurvival Outcomes Among Human Papillomavirus-Associated Oropharyngeal Squamous Cell Cancer Patients Treated with Upfront Surgery Versus Definitive Chemoradiation Therapy
Kelly J, An Y, Park H, Yarbrough W, Burtness B, Husain Z. Survival Outcomes Among Human Papillomavirus-Associated Oropharyngeal Squamous Cell Cancer Patients Treated with Upfront Surgery Versus Definitive Chemoradiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: s43-s44. DOI: 10.1016/j.ijrobp.2017.06.114.Peer-Reviewed Original ResearchPTEN loss as a predictive biomarker in head and neck squamous cell cancer (HNSCC) patients treated with cetuximab (C).
Eze N, Chung C, Neumeister V, Sandoval-Schaefer T, Lee J, Burtness B. PTEN loss as a predictive biomarker in head and neck squamous cell cancer (HNSCC) patients treated with cetuximab (C). Journal Of Clinical Oncology 2017, 35: e17520-e17520. DOI: 10.1200/jco.2017.35.15_suppl.e17520.Peer-Reviewed Original ResearchM HNSCCHazard ratioPTEN lossPTEN analysisLow tumorsExact testHigh tumorNeck squamous cell cancer patientsSquamous cell cancer patientsCox proportional hazards modelWild-type patientsHigh expression groupProportional hazards modelFisher's exact testPTEN testingC therapyFirst tertilePatient selectionKaplan-MeierType patientsCancer patientsPredictive biomarkersPIK3CA mutationsExpression groupHazards model
2015
Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients.
Seiwert T, Burtness B, Weiss J, Eder J, Yearley J, Murphy E, Nebozhyn M, McClanahan T, Ayers M, Lunceford J, Mehra R, Heath K, Cheng J, Chow L. Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. Journal Of Clinical Oncology 2015, 33: 6017-6017. DOI: 10.1200/jco.2015.33.15_suppl.6017.Peer-Reviewed Original ResearchEGFR-directed antibodies increase the risk of severe infection in cancer patients
Altan M, Burtness B. EGFR-directed antibodies increase the risk of severe infection in cancer patients. BMC Medicine 2015, 13: 37. PMID: 25857245, PMCID: PMC4336483, DOI: 10.1186/s12916-015-0276-9.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorSevere infectionsMonoclonal antibodiesRole of EGFRDose modification strategiesMonoclonal antibody treatmentClinical trial designRisk of infectionPractice of oncologyGrowth factor receptorConstitutional symptomsAntibody treatmentHypersensitivity reactionsCancer patientsRadiation therapyTrial designSolid tumorsInfection riskInfectionFactor receptorAntibodiesFurther studiesPatientsRiskRelated articles
2014
Freedom from recurrence after induction cisplatin/5-FU/RT versus carboplatin/paclitaxel/RT in patients with esophageal cancer.
Thomay A, Su S, Friedant A, Ruth K, Astsaturov I, Burtness B, Denlinger C, Dotan E, Hall M, Meyer J, Shah P, Cohen S, Scott W. Freedom from recurrence after induction cisplatin/5-FU/RT versus carboplatin/paclitaxel/RT in patients with esophageal cancer. Journal Of Clinical Oncology 2014, 32: 126-126. DOI: 10.1200/jco.2014.32.3_suppl.126.Peer-Reviewed Original ResearchEsophageal cancerOverall survivalGroup BLandmark analysisGroup ANeoadjuvant treatment regimenKaplan-Meier methodEsophageal cancer patientsProspective databaseR0 resectionDistant recurrencePatient demographicsSurgery patientsMeier methodMore recurrencesOperative complicationsPathologic responseTreatment regimenCancer patientsOperative procedurePatientsLarge seriesRecurrenceSurvival curvesPropensity score
2012
Informational needs of head and neck cancer patients
Fang CY, Longacre ML, Manne SL, Ridge JA, Lango MN, Burtness BA. Informational needs of head and neck cancer patients. Health And Technology 2012, 2: 57-62. PMID: 22518350, PMCID: PMC3327509, DOI: 10.1007/s12553-012-0020-9.Peer-Reviewed Original ResearchHNSCC patientsNeck squamous cell carcinomaEarly-stage diseaseMajority of patientsSquamous cell carcinomaConsiderable functional impairmentNeck cancer patientsInformational needsPatients' informational needsQuality of lifeInternet-based programAdvanced diseaseMost patientsYounger patientsMale patientsFemale patientsMajority of participantsCell carcinomaPatient populationCancer patientsTreatment optionsFunctional impairmentPatientsPsychosocial needsEmotional stress
2011
Psychological functioning of caregivers for head and neck cancer patients
Longacre ML, Ridge JA, Burtness BA, Galloway TJ, Fang CY. Psychological functioning of caregivers for head and neck cancer patients. Oral Oncology 2011, 48: 18-25. PMID: 22154127, PMCID: PMC3357183, DOI: 10.1016/j.oraloncology.2011.11.012.Peer-Reviewed Original ResearchConceptsPoor psychological healthPsychological healthPoorer psychological health outcomesCaregivers' psychological healthPsychological health outcomesPsychological functioningAnxious symptomsSocial supportCaregiver outcomesCurrent findingsLongitudinal studyHNSCC patientsFamily caregiversPositive benefitsCaregiversNeck squamous cell carcinomaSquamous cell carcinomaNeck cancer patientsPost-treatment periodHealth outcomesCancer patientsCell carcinomaCancer recurrenceGeneral populationPatients
2010
Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients
Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE. Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. Cancer Epidemiology Biomarkers & Prevention 2010, 19: 358-365. PMID: 20086114, PMCID: PMC2846615, DOI: 10.1158/1055-9965.epi-09-0937.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCetuximabColorectal NeoplasmsErbB ReceptorsErlotinib HydrochlorideGefitinibHead and Neck NeoplasmsHumansKaplan-Meier EstimateLung NeoplasmsMass SpectrometryMutationProtein Kinase InhibitorsProteomicsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)QuinazolinesRas ProteinsSignal TransductionSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationConceptsCRC patientsColorectal cancerCancer patientsNon-small cell lung cancer patientsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsNon-small cell lung cancerRecurrent/metastatic headCell lung cancer patientsNeck squamous cell carcinomaLigand levelsReceptor tyrosine kinase inhibitorsCell lung cancerSquamous cell carcinomaLung cancer patientsKRAS mutation statusTyrosine kinase inhibitorsProteomic classificationSerum proteomic profilesDiverse cancer typesSite of originChemotherapy cohortMetastatic headPretreatment serumSurvival benefit
2005
Analysis of epidermal growth factor receptor (EGFR) pathway in oropharyngeal squamous cell cancer patients in vivo (OSCC)
Psyrri A, Yu Z, Haffty B, Sasaki C, Weinberger P, Camp R, Rimm D, Burtness B. Analysis of epidermal growth factor receptor (EGFR) pathway in oropharyngeal squamous cell cancer patients in vivo (OSCC). Journal Of Clinical Oncology 2005, 23: 5518-5518. DOI: 10.1200/jco.2005.23.16_suppl.5518.Peer-Reviewed Original ResearchPregnancy-Associated Breast Cancer
Psyrri A, Burtness B. Pregnancy-Associated Breast Cancer. The Cancer Journal 2005, 11: 83-95. PMID: 15969981, DOI: 10.1097/00130404-200503000-00001.Peer-Reviewed Original ResearchConceptsPregnant breast cancer patientsBreast cancer patientsBreast cancerThird trimesterCancer patientsPregnancy-Associated Breast CancerSubsequent breast cancer developmentBreast massesClinical Oncology meetingsFirst antenatal visitHigh-risk diseaseImpact of pregnancyRisk of recurrenceHigh-risk groupBreast cancer riskPalpable breast massesBRCA2 mutation carriersBreast cancer developmentThorough breast examinationAntenatal visitsBreast conservationClinical presentationSubsequent pregnancyEarly pregnancyOncology meetings
2004
Sequence of Radiotherapy With Tamoxifen in Conservatively Managed Breast Cancer Does Not Affect Local Relapse Rates
Ahn PH, Vu HT, Lannin D, Obedian E, DiGiovanna MP, Burtness B, Haffty BG. Sequence of Radiotherapy With Tamoxifen in Conservatively Managed Breast Cancer Does Not Affect Local Relapse Rates. Journal Of Clinical Oncology 2004, 23: 17-23. PMID: 15545666, DOI: 10.1200/jco.2005.09.048.Peer-Reviewed Original ResearchConceptsConservative surgeryFree rateBreast cancerYale-New Haven HospitalSequence of radiotherapyLocal relapse rateCompletion of radiationBreast cancer patientsOverall survivalMargin statusNodal statusRelapse rateConcurrent administrationT stageRetrospective studyCancer patientsProgesterone statusPatientsStage ITamoxifenLocal controlConcurrent useCancer cellsSignificant differencesCancerImproved method for the detection of cytokeratin 19-positive cells in the peripheral blood of breast cancer patients
Alvero AB, Burtness BA, Ercan AG, Sapi E. Improved method for the detection of cytokeratin 19-positive cells in the peripheral blood of breast cancer patients. Laboratory Investigation 2004, 84: 658-661. PMID: 15105816, DOI: 10.1038/labinvest.3700086.Peer-Reviewed Original ResearchConceptsBreast cancer patientsQuantitative real-time reverse transcription-polymerase chain reactionCancer patientsDisease-free survivalReal-time reverse transcription-polymerase chain reactionReverse transcription-polymerase chain reactionDetection of cytokeratinClinical parametersPeripheral bloodPolymerase chain reactionCytokeratin 19PatientsTumor cellsChain reactionImproved assayAssaysCellsTherapyCytokeratinBlood
2000
The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function
Rose M, Lee F, Gollerkeri A, D'Andrea E, Psyrri A, Bdolah-Abram T, Burtness B. The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function. Bone Marrow Transplantation 2000, 26: 133-139. PMID: 10918422, DOI: 10.1038/sj.bmt.1702449.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCombined Modality TherapyCyclophosphamideDoxorubicinFemaleFollow-Up StudiesHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHumansMiddle AgedNeutropeniaPaclitaxelStroke VolumeSurvival RateVentricular Dysfunction, LeftConceptsLeft ventricular ejection fractionHigh-dose chemotherapyBreast cancer patientsMean absolute decreaseCancer patientsAbsolute decreaseLV functionCell rescueImpaired left ventricular functionHigh-dose thiotepaImpaired LV functionHigh-dose melphalanStem cell rescueSymptomatic heart failureCourses of chemotherapyVentricular ejection fractionLeft ventricular functionSequential paclitaxelMetastatic diseaseCardiac deathCardiac symptomsEjection fractionHeart failureVentricular functionCardiac toxicityTransplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial
Yanovich S, Mitsky P, Cornetta K, Maziarz R, Rosenfeld C, Krause D, Lotz J, Bitran J, Williams S, Preti R, Somlo G, Burtness B, Mills B. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. Bone Marrow Transplantation 2000, 25: 1165-1174. PMID: 10849529, DOI: 10.1038/sj.bmt.1702415.Peer-Reviewed Original ResearchConceptsHigh-risk breast cancer patientsBreast cancer patientsMedian timeCancer patientsIsolated CD34Clinical trialsCell selection systemHematopoietic reconstitutionHigh-risk breast cancerCapacity of CD34Transplantation of CD34Absolute neutrophil countDuration of hospitalizationHigh-dose chemotherapyMulticenter clinical trialBone Marrow Transplantation (2000) 25Incidence of infectionPeripheral blood cellsInter-group differencesProgenitor cell graftsPlatelet engraftmentNeutrophil countCell transplantPlatelet transfusionsPlatelet count
1998
Cytosine Deaminase Adenoviral Vector and 5-Fluorocytosine Selectively Reduce Breast Cancer Cells 1 Million-Fold When They Contaminate Hematopoietic Cells: A Potential Purging Method for Autologous Transplantation
Garcia-Sanchez F, Pizzorno G, Fu SQ, Nanakorn T, Krause DS, Liang J, Adams E, Leffert JJ, Yin LH, Cooperberg MR, Hanania E, Wang WL, Won JH, Peng XY, Cote R, Brown R, Burtness B, Giles R, Crystal R, Deisseroth AB. Cytosine Deaminase Adenoviral Vector and 5-Fluorocytosine Selectively Reduce Breast Cancer Cells 1 Million-Fold When They Contaminate Hematopoietic Cells: A Potential Purging Method for Autologous Transplantation. Blood 1998, 92: 672-682. PMID: 9657770, DOI: 10.1182/blood.v92.2.672.Peer-Reviewed Original ResearchMeSH KeywordsAdenoviridaeAnimalsAntimetabolites, AntineoplasticBreast NeoplasmsCell DeathCytosine DeaminaseFemaleFlucytosineFluorouracilGene Transfer TechniquesGenetic VectorsHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHematopoietic Stem CellsHumansMaleMiceNucleoside DeaminasesProdrugsTransplantation, AutologousTumor Cells, CulturedConceptsBreast cancer cellsPeripheral blood mononuclear cellsBreast cancer patientsCancer patientsCytosine deaminase geneHuman mammary epithelial cellsAdenoviral vectorCancer cellsHours of exposureHematopoietic cellsAutologous stem cell productsMarrow cellsEscherichia coli cytosine deaminase geneReplication-incompetent adenoviral vectorEpithelial cellsChemotherapy-induced myelosuppressionBreast cancer cell line MCF-7Blood mononuclear cellsEarly hematopoietic precursor cellsMale donor miceCancer cell line MCF-7Fluorescence-activated cell sorting (FACS) analysisMCF-7 breast cancer cellsNormal human mammary epithelial cellsMDA-MB-453